Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ilorasertib
- Development stage
- Phase 1
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ilorasertib is an orally bioavailable, ATP-mimetic small molecule that acts as a multitargeted kinase inhibitor. It selectively inhibits Aurora kinases (A, B, and C), vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and the Src family of tyrosine kinases. By inhibiting these targets, ilorasertib disrupts mitotic checkpoint control and angiogenesis pathways critical for tumor cell proliferation and survival. Developed by AbbVie (originating from Abbott Laboratories) as an antineoplastic agent, it has been investigated primarily in hematologic malignancies such as acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS), as well as in advanced solid tumors. Clinical trials reached up to phase II before development was discontinued for solid tumors[1][2][3][4][5][7].
- Other names
- ilorasertibIlorasertib [USAN]1227939-82-3
02
Targets
AURKB (Aurora kinase B)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)SFK (SRC family kinases)PDGFRA (Platelet-derived growth factor receptor alpha)CSF1R (Macrophage colony-stimulating factor receptor)VEGFR3 (Vascular endothelial growth factor receptor 3)AURKA (Aurora kinase A)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)AURKC (Aurora kinase C)
Beyond the preview
Go deeper on ilorasertib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ilorasertib.